Poster

Patient-reported depressive symptoms among individuals diagnosed with Major Depressive Disorder with and without prominent anhedonia using a real-world dataset

Abstract: Anhedonia is a core feature of major depressive disorder (MDD). However, little is known about its related symptom burden and its impact on patients’ clinical trajectory. This r...

08/20/2024

Pharmacokinetics and Safety of LY03010, a Novel Monthly Intramuscular Injectable Extended-release Paliperidone Palmitate Suspension in Patients with Schizophrenia or Schizoaffective Disorder

Abstract: LY03010 (paliperidone palmitate) is in development as a pharmaceutical equivalent drug product to the listed drug (LD), INVEGA SUSTENNA® for schizophrenia and schizoaffective di...

08/20/2024

Polypharmacy and deprescribing of cholinesterase inhibitors in dementia: a case report and literature review

Abstract: The patient is an 81-year-old female with a past medical history of dementia who presented to the hospital for a mechanical fall. Her medication reconciliation revealed she had ...

08/20/2024

Long-Term Efficacy of Esketamine Nasal Spray Among Early and Delayed Responders: A Subgroup Analysis of the SUSTAIN-3 Study

Abstract: Objective: To describe the long-term efficacy of esketamine nasal spray (ESK) in adult patients (aged 18-64 years) with treatment-resistant depression (TRD) dosed according to U...

08/20/2024

Preliminary data from the CONNEX-X extension trial examining the long-term safety of iclepertin (BI 425809) in patients with schizophrenia who completed Phase III CONNEX trials

Abstract: Introduction: Iclepertin (BI 425809), a glycine transporter-1 inhibitor, has improved cognitive impairment associated with schizophrenia (CIAS) in Phase II trials, with Phase II...

08/20/2024

Long-Term Safety and Efficacy of Esketamine Nasal Spray by Dosing Frequency in Adults With Treatment-Resistant Depression: Analysis of the SUSTAIN-3 Study

Abstract: Objective: To describe the long-term safety and efficacy of flexibly dosed esketamine nasal spray (ESK) in patients with treatment-resistant depression (TRD) from SUSTAIN-3 (NCT...

08/20/2024

Probiotics as an Adjuvant for Microbiota-gut-brain Axis Dysfunction in Depression

Abstract: Depression is a debilitating disorder, and it is expected to overtake cardiac illnesses as the top source of disease burden in 7 years. It is a psychiatric disorder that is diag...

08/20/2024

Long-Term Safety and Efficacy of Olanzapine/Samidorphan: Results of a 4-Year Open-Label Study

Abstract: Background: Long-term safety, tolerability, and durability of therapeutic effect are important aspects of antipsychotic treatment. Methods: This phase 3, multicenter, open-lab...

08/20/2024

Lumateperone in the Treatment of Patients With Major Depressive Disorder and Bipolar Disorder With Anxious Distress and Mixed Features

Abstract: Background: Lumateperone is an FDA-approved antipsychotic to treat schizophrenia and depressive episodes associated with bipolar I or bipolar II disorder (BD).

08/20/2024

Lumateperone Treatment for Major Depressive Episodes With Mixed Features in Major Depressive Disorder and Bipolar I or Bipolar II Disorder

Abstract: Background: Lumateperone is an FDA-approved antipsychotic to treat schizophrenia and depressive episodes associated with bipolar I or bipolar II disorder (BD). This randomized, ...

08/20/2024